Targeted Therapy of Acute Myeloid Leukemia (Current Cancer Research)

This book provides an unprecedented overview of targeted therapies for acute myeloid leukemias. The volume provides comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Authoritative chapters are written by leading research scientists and clinicians, who explain basic concepts and the clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML. The chapter topics include the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53, and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. In addition, chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells, and leukemia metabolism, provide insight into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies complete the overview of the multi-dimensional therapeutic landscape, where leukemia specialists develop treatment strategies, which are expected to bring forth critical breakthroughs in the field of leukemia.